rare disease

Immedica to Acquire Biopharma Company Marinus

Stockholm, Sweden-headquartered global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals, a US commercial-stage pharmaceutical company developing therapies for seizure disorders, for enterprise value of approximately $151 million.

News

Pfizer Doubles Dublin Biologicals Capacity

Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.

Topics • Strategy

After Pharma’s Patent Cliff

Top-Feature

Dow Chemical Company

From Data to Decisions: Digital Tools Reshaping the Chemical and Life Sciences Landscape

Sasol

Leading Transformation

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Nova-Institut GmbH

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Brenntag SE

Brenntag Downsizes Management Board, Retains Both Divisions

Expert Insights

Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Immedica Pharma AB

SchüllerConsulting

rare disease

Immedica to Acquire Biopharma Company Marinus

Pfizer Doubles Dublin Biologicals Capacity

After Pharma’s Patent Cliff

Top-Feature

Anchored in Sustainability

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

API Manufacturing

Leading the way. Driving results.

Welcome to the World of Laboratories: Analytica 2026